T. Rowe Price Associates
CANO

T. Rowe Price Associates’s Cano Health, Inc. CANO Stock Holding History

T. Rowe Price Associates’s Portfolio CANO Stock Details CANO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,693
Closed -$43K – 2963
2023
Q3 		$43K Buy
1,693
+24
+1% +$1.97K ﹤0.01% 2792
2023
Q2 		$232K Buy
1,669
+402
+32% +$51.6K ﹤0.01% 2473
2023
Q1 		$116K Buy
1,267
+445
+54% +$60.4K ﹤0.01% 2655
2022
Q4 		$113K Sell
822
-7,292
-90% -$2.47M ﹤0.01% 2692
2022
Q3 		$7.04M Buy
8,114
+7,302
+899% +$4.58M ﹤0.01% 1135
2022
Q2 		$356K Buy
812
+311
+62% +$162K ﹤0.01% 2376
2022
Q1 		$318K Buy
501
+174
+53% +$110K ﹤0.01% 2530
2021
Q4 		$291K Buy
+327
New +$344K ﹤0.01% 2600

Other funds holding CANO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

T. Rowe Price Associates's CANO Position: Q4 2023 in Review

T. Rowe Price Associates sold out of Cano Health, Inc. (CANO) in Q4 2023, closing a stake of 1,693 shares — an estimated $43K sold.

T. Rowe Price Associates first reported a position in CANO in Q4 2021 and held it in 8 quarters. The position peaked at $7.04M in Q3 2022. 50 funds tracked by Wall St. Rank hold CANO as of Q4 2023.

  • T. Rowe Price Associates reported no remaining Cano Health, Inc. position as of Q4 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,693 Cano Health, Inc. shares in Q4 2023, an estimated $43K.
  • T. Rowe Price Associates first reported a position in Cano Health, Inc. in Q4 2021 and held it in 8 quarters.
  • T. Rowe Price Associates's Cano Health, Inc. position peaked at $7.04M in Q3 2022.
  • 50 funds tracked by Wall St. Rank held Cano Health, Inc. as of Q4 2023.

Based on T. Rowe Price Associates's 13F filing for Q4 2023, filed 14 Feb 2024.